SOCRA CCRP Exam Dumps

Drug storage conditions are essential to maintaining investigational product (IP) integrity. According to ICH:

ICH E6(R2) 5.13.3: ''The sponsor should ensure that investigational products are stored... under appropriate conditions as specified by the sponsor and in accordance with applicable regulatory requirement(s).''

ICH E6(R2) 4.6.4: ''The investigator/institution should store the investigational product(s) as specified by the sponsor (and in accordance with applicable regulatory requirement(s)), and ensure that product(s) are used only in accordance with the approved protocol.''

During site qualification/selection, the monitor evaluates storage conditions --- particularly temperature ranges --- to ensure the site can meet the stability requirements for the IP. Factors like staff numbers, space, and cost are operational considerations but not regulatory determinants of site qualification.

Thus, the correct answer is C (Storage facility temperature range). This ensures compliance with sponsor specifications, product stability, and ultimately subject safety.

ICH E6(R2), 5.13.3 (Product storage requirements).

ICH E6(R2), 4.6.4 (Investigator product storage responsibilities).

ICH E6(R2) 5.13.3: The sponsor is responsible for the supply, storage, and final disposition of investigational product.

21 CFR 312.59: Sponsors must assure return or proper disposition of unused supplies.

Sites must follow sponsor's written procedures for reconciliation, return, or destruction, not IRB or pharmacy processes.

21 CFR 54.4(b): Requires disclosure during the study and for 1 year after completion.

After three years, no disclosure is required.

ICH E6(R2) 4.6.1: ''Responsibility for investigational product accountability at the trial site rests with the investigator.''

May delegate to pharmacist or coordinator, but ultimate responsibility lies with investigator.

Phase IV studies (post-marketing) examine real-world safety and effectiveness.

ICH E8(R1): Describes Phase IV as ''studies performed after drug approval to delineate additional information including the drug's risks, benefits, and optimal use.''

They often test drugs in new or broader populations beyond original approval.

While dosing and schedules are Phase I--III, Phase IV focuses on new patient populations or long-term outcomes.